News & Events
- Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
- Correction: Genetic Analysis announces placement of a directed share issue of NOK 12.8 million
- Genetic Analysis announces proposed changes to the Board
- Notice of annual general meeting
- Genetic Analysis announces proposed changes to the Board
- Genetic Analysis announces placement of a directed share issue of NOK 12.8 million
- Genetic Analysis AS publishes Annual Report 2024
- Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
- Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
- Genetic Analysis AS and Thalys Medical Technology Group are pleased to announce the launch of a microbiome test to the Chinese Consumer Health market
- Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
- Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
- Genetic Analysis AS publishes year-end report 2024
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale